New drug trial offers hope for rare pancreatic cancer patients
NCT ID NCT07121478
Summary
This study is testing whether the drug lurbinectedin can help control advanced pancreatic neuroendocrine tumors in patients whose previous treatments have stopped working. The trial will enroll 46 participants with high-grade tumors to measure how well the drug shrinks tumors and controls disease progression. This is a Phase 2 study, meaning researchers are gathering evidence about whether this approach is effective enough to move to larger trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMOR OF PANCREAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
Conditions
Explore the condition pages connected to this study.